Dr Núria Amigó will be giving a Seminar on December 3rd, 11am – 11:45am. Her talk will be on NMR metabolomics: Applications and uses for cardio-metabolic research and as a screening tool in clinical practice.
This event will take place in Seminar Room 10A\10B in the Commonwealth Building.
Abstract:
Metabolomics provides a comprehensive view of an individual’s phenotype, being the omics discipline that best captures their biological reality, as metabolites represent the final products of the dynamic interaction between gene expression, metabolic pathways, and environmental factors. This ability to integrate genetic and environmental information makes metabolomics a powerful and promising tool for the development of diagnostic clinical applications, facilitating the identification of specific molecular signatures associated with complex and multifactorial diseases.
In this seminar, the development and implementation of Nuclear Magnetic Resonance (NMR) as a high-performance, cost-competitive analytical technology in the field of metabolomics will be analyzed, with a special emphasis on its integration into advanced clinical environments. Additionally, the crucial role of this technology in advanced molecular characterization, including comprehensive lipoprotein profiling, will be addressed. This contributes significantly to early diagnosis, risk stratification, prevention, and optimization of therapeutic resources in patient management, playing an essential role in personalized medicine.
Bio: Dr. Núria Amigó Grau is a physicist and biomedical engineer specializing in cardiovascular diagnostics and lipidomics. Since January 2022, she has been an elected member of the European Lipoprotein Club Organizing Committee and has served on the Lipoprotein and Vascular Disease Commission of the Sociedad Española de Medicina de Laboratorio since May 2021. An Associate Professor in Biostatistics at the Faculty of Medicine and Health Sciences, Rovira i Virgili University, Dr. Amigó also leads Biosfer Teslab as Managing and Scientific Director. As a co-founder, she played a pivotal role in developing the Liposcale test, an advanced lipoprotein diagnostic tool she initially worked on during her PhD. This spin-off company, affiliated with Rovira i Virgili University and the Pere Virgili Health Research Institute, provides innovative analytical services for assessing lipid metabolism and cardiovascular risk via Nuclear Magnetic Resonance (NMR) spectroscopy.
Dr. Amigó’s career includes significant research collaborations, including participation in collaborative European projects (i.e AtheroNet Cost Action and CardioSCOPE MSCA projects). Additionally, during her PhD, she contributed to cardiovascular prevention research at Brigham and Women’s Hospital/Harvard Medical School in Boston. Under her guidance, Biosfer Teslab achieved CE certification for the Liposcale test and approval from the Spanish Agency of Medicines and Medical Devices to manufacture diagnostic software.
Dr. Amigó’s expertise spans biomedical research, biomarker discovery, and machine learning applications in cardiovascular research. She currently leads two major projects focused on R&D and commercialization of in vitro diagnostic tests. Her contributions have been widely recognized, including her selection for the international business accelerator, The Big Booster, and an esteemed award from the Catalan Foundation Gresol in 2016 for Young Academic Talent. In 2019, she was also honored with The Innovation Prize by the Elzaburu Foundation, underscoring her impactful work in advancing health diagnostics and biotech innovation.